Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,165
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab

Angel Luis Salcedo-Mingoarranza Pharmacy Department, Severo Ochoa University Hospital, Leganés, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2343-5897View further author information
ORCID Icon,
María Dorado-Fernándezb Dermatology Department, Severo Ochoa University Hospital, Leganés, SpainView further author information
,
Sofía García-Martíneza Pharmacy Department, Severo Ochoa University Hospital, Leganés, SpainView further author information
,
Paz Collado-Ramosc Rheumatology Department, Severo Ochoa University Hospital, Leganés, SpainView further author information
&
Nicolás Silvestre-Tornerb Dermatology Department, Severo Ochoa University Hospital, Leganés, SpainView further author information
Article: 2242705 | Received 08 Jun 2023, Accepted 25 Jul 2023, Published online: 08 Aug 2023

References

  • Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment and follow-up. Allergy. 2013;68(5):1–4. doi: 10.1111/all.12129.
  • Lipsker D. The schnitzler syndrome. Orphanet J Rare Dis. 2010;5(1):38. doi: 10.1186/1750-1172-5-38.
  • Rowczenio DM, Pathak S, Arostegui JI, et al. Molecular genetic investigation, clinical features and response to treatment in 21 patients with schnitzler syndrome. Blood. 2018;131(9):974–981. doi: 10.1182/blood-2017-10-810366.
  • De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in schnitzler’s syndrome. Ann Rheum Dis. 2013;72(10):1634–1638. doi: 10.1136/annrheumdis-2012-202192.
  • Krause K, Tsianakas A, Wagner N, et al. Efficacy and safety of canakinumab in schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2017;139(4):1311–1320. doi: 10.1016/j.jaci.2016.07.041.
  • Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10(10):19. doi: 10.1186/s13023-015-0228-7.
  • Gusdorf L, Lipsker D. Schnitzler syndrome: a review. Curr Rheumatol Rep. 2017;19(8):46. doi: 10.1007/s11926-017-0673-5.
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. doi: 10.1146/annurev.immunol.021908.132612.
  • Loock J, Lamprecht P, Timmann C, et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with schnitzler syndrome. J Allergy Clin Immunol. 2010;125(2):500–502. doi: 10.1016/j.jaci.2009.10.066.
  • Martínez-Taboada VM, Fontalba A, Blanco R, et al. Successful treatment of refractory schnitzler syndrome SchS with anakinra: comment on the article by hawkings et al. Arthritis Rheum. 2005;52(7):2226–2227. doi: 10.1002/art.21101.
  • Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in schnitzler’s syndrome: a french multicenter study. Autoimmun Rev. 2014;13(10):1035–1041. doi: 10.1016/j.autrev.2014.08.031.
  • Gouveia AI, Micaelo M, Pierdomenico F, et al. Schnitzler síndrome: a dramatic response to anakinra. Dermatol Ther (Heidelb). 2016;6(2):299–302. doi: 10.1007/s13555-016-0108-7.
  • Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):636–642. doi: 10.1016/j.semarthrit.2020.05.002.
  • Vanderschueren S, Knockaert D. Canakinumab in schnitzler syndrome. Semin Arthritis Rheum. 2013;42(4):413–416. doi: 10.1016/j.semarthrit.2012.06.003.
  • Krause K, Bonnekoh H, Ellrich A, et al. Long-term efficacy of canakinumab in the treatment of schnitzler syndrome. J Allergy Clin Immunol. 2020;145(6):1681–1686.e5. doi: 10.1016/j.jaci.2019.12.909.
  • de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4(4):41. doi: 10.1186/2045-7022-4-41.
  • Gellrich FF, Günther C. Schnitzler syndrome. Hautarzt. 2019;5 doi: 10.1007/s00105-019-4434-4.
  • Pesek R, Fox R. Successful treatment of schnitzler syndrome with canakinumab. Cutis. 2014;94(3):E11–2.
  • Thomsen SF, Duhn PH, Kristensen J. A 51-Year old woman with schnitzler syndrome treated with canakinumab. Open Dermatol J. 2011;5:31–32.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.